Journal article
Continued Benefit From Paclitaxel-Eluting Compared With Bare-Metal Stent Implantation in Saphenous Vein Graft Lesions During Long-Term Follow-Up of the SOS (Stenting of Saphenous Vein Grafts) Trial
JACC. Cardiovascular interventions, Vol.4(2), pp.176-182
02/2011
DOI: 10.1016/j.jcin.2010.10.003
PMID: 21349456
Abstract
This study sought to report the long-term outcomes after drug-eluting stent (DES) implantation in saphenous vein graft (SVG) lesions in the SOS (Stenting of Saphenous Vein Grafts) trial.
The long-term outcomes after DES implantation in SVGs are poorly studied. Apart from the SOS trial, the only other randomized trial comparing DES with bare-metal stents (BMS) in SVGs reported higher mortality in the DES group at 32 months.
In the SOS trial, 80 patients with 112 lesions in 88 SVGs were randomized to a BMS or paclitaxel-eluting stent (PES) and demonstrated improved short-term angiographic and clinical outcomes with PES. Extended clinical follow-up was subsequently obtained.
Mean age was 67 ± 9 years, and all patients were men. The indications for stenting included acute coronary syndrome in 60% and stable angina in 31% of patients. The mean SVG age was 12 ± 6 years. The baseline characteristics of the patients in the 2 study groups were similar. Procedural success was achieved in 77 patients (96%). During a median follow-up of 35 months, compared with patients randomized to BMS, those receiving PES had a lower incidence of myocardial infarction (hazard ratio [HR]: 0.32, p = 0.01), target lesion revascularization (HR: 0.20, p = 0.004), target vessel revascularization (HR: 0.41, p = 0.03), and target vessel failure (HR: 0.34, p = 0.001) as well as a trend toward less definite or probable stent thrombosis (HR: 0.15, p = 0.08). All-cause mortality (HR: 2.04, p = 0.19) and cardiac mortality (HR: 0.62, p = 0.51) did not differ between groups.
During long-term follow-up, use of PES was associated with significantly better clinical outcomes than BMS in SVG lesions. (Stenting of Saphenous Vein Grafts Trial [SOS]; NCT00247208)
Details
- Title: Subtitle
- Continued Benefit From Paclitaxel-Eluting Compared With Bare-Metal Stent Implantation in Saphenous Vein Graft Lesions During Long-Term Follow-Up of the SOS (Stenting of Saphenous Vein Grafts) Trial
- Creators
- Emmanouil S. Brilakis - Internal MedicineChristopher Lichtenwalter - Raytheon TechnologiesAbdul-rahman R. Abdel-karim - Raytheon TechnologiesJames A. de Lemos - Internal MedicineOwen Obel - The University of Texas Southwestern Medical CenterTayo Addo - Internal MedicineMichele Roesle - Raytheon TechnologiesDonald Haagen - Raytheon TechnologiesBavana V. Rangan - VA North Texas Health Care SystemBilal Saeed - University of ToledoJoseph K. Bissett - Department of Cardiovascular Diseases, Central Arkansas Veterans Healthcare System and University of Arkansas for Medical Sciences, Little Rock, ArkansasRajesh Sachdeva - University of Arkansas for Medical SciencesVassilios V. Voudris - Onassis Cardiac Surgery CenterPanagiotis Karyofillis - Onassis Cardiac Surgery CenterBiswajit Kar - VA Medical CenterJames Rossen - VA Medical CenterPanayotis Fasseas - Medical College of WisconsinPeter Berger - Geisinger Medical CenterSubhash Banerjee - Internal Medicine
- Resource Type
- Journal article
- Publication Details
- JACC. Cardiovascular interventions, Vol.4(2), pp.176-182
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.jcin.2010.10.003
- PMID
- 21349456
- ISSN
- 1936-8798
- eISSN
- 1876-7605
- Grant note
- AstraZeneca The Medicines Company Boston Scientific Haemoscope Mdcareglobal (spouse) Thrombovision Accumetrics Harris Methodist Foundation Hygeiatel Department of Veterans Affairs VISN-17 Startup Award Helena Corgenix/Aspirinworks
- Language
- English
- Date published
- 02/2011
- Academic Unit
- Neurology; Cardiovascular Medicine; Neurosurgery; Internal Medicine
- Record Identifier
- 9984302212202771
Metrics
7 Record Views